Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy

Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical trials in patients with advanced ALK- or ROS1-rearrangement NSCLC ind...

Полное описание

Библиографические подробности

Главные авторы:	Woo Kyung Ryu, Hyungkeun Cha, Mi Hwa Park, Jung Soo Kim, Jeong-Seok Choi, Lucia Kim, Kyung-Hee Lee, Hae-Seong Nam
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2022-10-01
Серии:	Frontiers in Oncology
Предметы:	interstitial lung disease (ILD) ALK (anaplastic lymphoma kinase) ROS1 tyrosine kinase inhibitor (TKI) crizotinib
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fonc.2022.900966/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!